Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avadel Pharmaceuticals (AVDL) Total Non-Current Liabilities: 2009-2022

Historic Total Non-Current Liabilities for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Sep 2022 value amounting to $152.5 million.

  • Avadel Pharmaceuticals' Total Non-Current Liabilities fell 5.38% to $152.5 million in Q3 2022 from the same period last year, while for Sep 2022 it was $152.5 million, marking a year-over-year decrease of 5.38%. This contributed to the annual value of $165.1 million for FY2021, which is 13.74% up from last year.
  • As of Q3 2022, Avadel Pharmaceuticals' Total Non-Current Liabilities stood at $152.5 million, which was down 1.98% from $155.6 million recorded in Q2 2022.
  • Avadel Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $250.6 million during Q1 2018, with a 5-year trough of $145.2 million in Q4 2020.
  • In the last 3 years, Avadel Pharmaceuticals' Total Non-Current Liabilities had a median value of $155.6 million in 2022 and averaged $157.2 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first grew by 29.07% in 2018, then plummeted by 31.90% in 2019.
  • Quarterly analysis of 5 years shows Avadel Pharmaceuticals' Total Non-Current Liabilities stood at $173.5 million in 2018, then declined by 1.01% to $171.8 million in 2019, then decreased by 15.49% to $145.2 million in 2020, then grew by 13.74% to $165.1 million in 2021, then decreased by 5.38% to $152.5 million in 2022.
  • Its Total Non-Current Liabilities was $152.5 million in Q3 2022, compared to $155.6 million in Q2 2022 and $162.0 million in Q1 2022.